New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drugs in R&D

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2165/0126839-200809060-00004PMID 18989990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method

  2007cited by this paper
• Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

  2007cited by this paper
• Identification and removal of immunogenicity in therapeutic proteins.

  2007cited by this paper
• Humanized E17 Hemophilic Mice Are a Major Breakthrough in the Design of New Preclinical Models for Developing Factor VIII Products with Reduced Immunogenicity.

  2007cited by this paper
• Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays.

  2007cited by this paper
• The Rebif® New Formulation Story

  2007cited by this paper
• Scientific and regulatory considerations on the immunogenicity of biologics.

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′

  2006cited by this paper
• Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

  2006cited by this paper
• Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity

  2005cited by this paper
• Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII

  2005cited by this paper
• Query3d: a new method for high-throughput analysis of functional residues in protein structures

  2005cited by this paper
• Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity

  2005cited by this paper
• Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

  2005cited by this paper
• Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta

  2005cited by this paper
• Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C

  2005cited by this paper
• Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b

  2005cited by this paper
• Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine: Preliminary findings of a Phase I safety/immunogenicity trial.

  2004cited by this paper
• Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles

  2004cited by this paper
• Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.

  2004cited by this paper
• Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope

  2004cited by this paper
• Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice

  2004cited by this paper
• The Development of a Modified Human IFN-α2b Linked to the Fc Portion of Human IgG1 as a Novel Potential Therapeutic for the Treatment of Hepatitis C Virus Infection

  2004cited by this paper
• The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4+ T-cell epitope in human interferon-β

  2004cited by this paper
• Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

  2003cited by this paper
• Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

  2003cited by this paper
• Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.

  2003cited by this paper
• A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions

  2003cited by this paper
• Prediction of MHC class I binding peptides using profile motifs.

  2002cited by this paper
• Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

  2002cited by this paper
• Von Willebrand Factor Modulates Factor VIII Immunogenicity: Comparative Study of Different Factor VIII Concentrates in a Haemophilia A Mouse Model

  2002cited by this paper
• Thrombocytopenia caused by the development of antibodies to thrombopoietin

  2002cited by this paper
• ProPred: prediction of HLA-DR binding sites

  2001cited by this paper
• Thrombocytopenia caused by the development of antibodies to thrombopoietin.

  2001cited by this paper
• Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.

  2000cited by this paper
• Major histocompatibility complex class II polymorphisms in primates

  1999cited by this paper
• Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.

  1999cited by this paper
• Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

  1999cited by this paper
• Neutralizing antiviral B cell responses.

  1997cited by this paper
• Neutralising and binding anti-interferon-β-1 b (IFN-b-1 b) antibodies during IFN-β-1 b treatment of multiple sclerosis

  1997cited by this paper
• Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.

  1997cited by this paper
• Nonhuman primate models to evaluate vaccine safety and immunogenicity.

  1997cited by this paper
• Anti-interferon-gamma antibodies in a patient undergoing interferon-gamma treatment for systemic mastocytosis.

  1996cited by this paper
• Anti-Interferon-γ Antibodies in a Patient Undergoing Interferon-γ Treatment for Systemic Mastocytosis

  1996cited by this paper
• CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.

  1995cited by this paper
• Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

  1995cited by this paper
• On the Immunogenicity of Recombinant Staphylokinase in Patients and in Animal Models

  1994cited by this paper
• Utilization of homologous proteins to evaluate the safety of recombinant human proteins--case study: recombinant human interferon-gamma (rhIFN-gamma).

  1992cited by this paper
• Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.

  1990cited by this paper
• Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants.

  1990cited by this paper

• FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

  2025cites this paper
• SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy

  2024cites this paper
• Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models.

  2024cites this paper
• A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

  2021cites this paper
• Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside.

  2021cites this paper
• A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

  2021cites this paper
• T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

  2020cites this paper
• In silico mutagenesis in recombinant human keratinocyte growth factor: Improvement of stability and activity in addition to decrement immunogenicity.

  2020cites this paper
• Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

  2020cites this paper
• Safety and Ef fi cacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study

  2020cites this paper
• Unwanted Immunogenicity: From Risk Assessment to Risk Management

  2019cites this paper
• Immunogenicity Risks for Naturally Derived Complex Drugs

  2019cites this paper
• The Science and Regulations of Naturally Derived Complex Drugs

  2019cites this paper
• Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

  2018cites this paper
• Humanization and Simultaneous Optimization of Monoclonal Antibody.

  2018cites this paper
• Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins

  2018cites this paper
• In silico and in vitro immunogenicity assessment of B‐domain‐modified recombinant factor VIII molecules

  2018cites this paper
• Mining the secretory proteins L.donovani for novel MHC class I restricted epitopes against visceral leishmaniasis

  2017cites this paper
• The Current State of Peptide Drug Discovery: Back to the Future?

  2017cites this paper
• In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies.

  2017cites this paper
• Immunogenicity Lessons Learned from the Clinical Development of Vatreptacog Alfa, A Recombinant Activated Factor VII Analog, in Hemophilia with Inhibitors

  2017cites this paper
• A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors

  2016cites this paper
• Engineering less immunogenic and antigenic FVIII proteins.

  2016cites this paper
• A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead

  2016cites this paper
• A Novel Humanized Antibody Neutralizes H5N1 Influenza Virus via Two Different Mechanisms

  2015influential citation
• Mapping the Pareto Optimal Design Space for a Functionally Deimmunized Biotherapeutic Candidate

  2015cites this paper
• Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity

  2015cites this paper
• Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.

  2015cites this paper
• Preclinical Immunogenicity Risk Assessement of Biotherapeutics

  2015cites this paper
• Immunoglobulin-based strategies for half-life extension of recombinant proteins

  2015cites this paper
• Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate

  2014cites this paper
• Humanization and simultaneous optimization of monoclonal antibody.

  2014cites this paper
• Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes

  2014cites this paper
• Immunogenicity of Protein Therapeutics: Risk Assessment and Risk Mitigation

  2014cites this paper
• Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases

  2014cites this paper
• Monoclonal antibody therapeutics with up to five specificities

  2013cites this paper
• Preclinical Safety Testing

  2013cites this paper
• Monoclonal antibody-related drugs for cancer therapy.

  2013cites this paper
• Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

  2013cites this paper
• T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.

  2013cites this paper
• Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses

  2012cites this paper
• Reducing Protein Immunogenicity by Design: Deimmunization and Tolerance Induction

  2012cites this paper
• 11 Synthetic Peptide Vaccines

  2012cites this paper
• Universal Immunoassay Applied During Early Development of Large Molecules to Understand Impact of Immunogenicity on Biotherapeutic Exposure

  2012cites this paper
• Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations.

  2012cites this paper
• Engineering the variable region of therapeutic IgG antibodies

  2011cites this paper
• Impact of product-related factors on immunogenicity of biotherapeutics.

  2011cites this paper
• Anticorps anti-endogline

  2010cites this paper
• Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

  2010cites this paper
• Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics.

  2010cites this paper
• Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

  2010cites this paper
• Synthetic peptide vaccines

  2010cites this paper
• Design of second generation therapeutic recombinant bone morphogenetic proteins.

  2009cites this paper
• A vaccine that delivers rather than induces antibodies

  2009cites this paper
• Circumventing immunogenicity in the development of therapeutic antibodies.

  2009cites this paper